Until now, de-identifying clinical trial data has involved writing one-off SAS programs or developing a library of SAS macros. But as the volume of requests increases for internal and external data sharing, this approach has become unsustainable. What teams really need is a definitive, efficient, repeatable, scalable and secure way of managing data de-identification.
Although some companies have adopted an outsourcing approach, this ultimately relies on these same traditional SAS programming methods - using highly proficient SAS programmers, and resulting in premium costs.
As long as organizations default to manual ways of managing data de-identification, they will leave themselves exposed to:
To address the growing demands for de-identification, the clinical trials experts at d-Wise have developed a powerful de-identification as-a-Service platform leveraging Blur.
The #1 solution in its field, Blur is designed to provide highly efficient, application-driven approach to de-identification. It has been built expressly for clinical trial data and documents and aligned with clinical trial de-identification guidelines from industry working groups.
Clients can license Blur through a software-as-a-Service model (SaaS), with the option to engage d‑Wise to deliver outsourced de-identification services using the Blur platform. This offers companies with limited capital or resources an efficient way to accelerate the delivery of redacted data for future studies, both internal and external.
To take advantage of the Blur de-identification as-a-service platform, teams simply need to provide us with clinical trial data sets via SFTP, Box.com, or a specified client-provided data exchange platform.
This data can conform to either the CDISC SDTM structure or a client-specific data structure. (Non-CDISC data will be subject to preliminary review by d-Wise experts, who will need to assess the complexity of the structure and any irregularities that may increase the work involved.)
The following supporting materials will be needed for each data set:
d-Wise will then process the submitted data using our own secure, compliant systems, according to an agreed subset of the guidance.
At the conclusion of the project, we’ll provide the following deliverables back to you using the original means of data transfer:
If you’re struggling to fulfill rising clinical data de-identification requirements or have a growing need to be able to re-use valuable data for other purposes including further research, d-Wise can rapidly and cost-effectively do the work for you – with the assurance of high quality, automated workflow and complete audit trails.
Let the clinical trial experts at d-Wise conveniently, and securely, anonymize your data in alignment with global working group requirements.
Download our datasheet to learn more.
No code to write. No syntax to learn.
De-identification, review and sign-off are built into the process.
Accelerate de-identification by applying templates from completed projects to new projects.
Support for PhUSE, TransCelerate and other industry rules is designed into the product.
With a broader resource pool, costs come down and efficiency goes up.
If there’s no sign-off by the reviewer, there’s no de-identified data to export.
Whether you're using CDISC or other internal standards, Blur enables you to reduce cost and time.
On-premise, in the cloud or provided as a service – d-Wise and Blur are designed to enable your success.
Blur takes the data as is, instead of requiring you to grind it into the right structure.
Menu-driven functionality limits how far you can wander from the ideal process.
Blur provides native support for reading and writing SAS data sets, SAS transport files, and more.
Detailed reports document all de-identification activities for downstream users and internal auditors.